Poll: Is the New Prenatal Blood Test for Trisomy 21 a Good Thing?

Article

A new prenatal blood test for trisomy 21 has been released in Europe, and it's targeted to women in their 12th week and beyond. Is it a good thing?

A new prenatal blood test for trisomy 21 has been developed for women in their 12th week and beyond who are at increased risk for carrying a fetus with Down Syndrome. The test, which is at least 95% accurate, has already been released in Europe by the German company LifeCodexx under the name PrenaTest. An international federation of Down Syndrome organizations appealed to the European Court of Human Rights to stop the release of the test, and some physicians and advocates are concerned that the test will lead to an increase of abortions.

The makers of the test encourage amniocentesis ad genetic counseling for any woman with a positive test result. Amniocentesis, which has been the primary method of detection for trisomy 21, has a 1% risk of fetal loss in the 16th week.


 

Online Poll

|

Online Survey

Recent Videos
Mirvie's RNA platform revolutionizes detection of fetal growth restriction | Image Credit: wexnermedical.osu.edu
How early genetic testing empowers parents and improves outcomes | Image Credit: tuftsmedicine.org
Dallas Reed highlights trends and barriers in prenatal genetic testing | Image Credit: tuftsmedicine.org
How maternal fetal medicine specialists improve outcomes for high-risk pregnancies | Image Credit: profiles.mountsinai.org
How the cobas liat assay panels improve STI detection | Image Credit: labqualityconfab.
Screening-to-diagnosis interval vital for gestational diabetes outcomes | Image Credit: ultracon2024.eventscribe.net
Henri M. Rosenberg, MD
Medical experts personalize contraceptive options for complex cases | Image Credit: findcare.ahn.org
Study explores the limits of neighborhood data in predicting preterm birth | Image Credit: linkedin.com
Barbed suture reduces blood loss in hysterectomy | Image Credit: linkedin.com
Related Content
© 2025 MJH Life Sciences

All rights reserved.